A pilot phase II study of capecitabine in advanced or recurrent gastric cancer

Oncology

Volumn 64, Issue 3, 2003, Pages 232-236

  Koizumi, Wasaburo ^a   Saigenji, Katsunori ^a   Ujiie, Shigeki ^b   Terashima, Masanori ^c   Sakata, Yu ^d   Taguchi, Tetsuo ^e  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Miyagi Cancer Center   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e Japan Soc for Cancer Chemotherapy   (Japan)

Author keywords

Capecitabine; Gastric cancer; Phase II study

Indexed keywords

CAPECITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; JAPAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SIDE EFFECT; SKIN TOXICITY; STOMACH CARCINOMA; SURVIVAL TIME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 0037265616     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069313     Document Type: Article

References (20)

1. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16:1795-1802.
2. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumor tissues. Chem Pharm Bull (Tokyo) 1983;31:175-178.
3. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
4. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
5. Cutsem EV, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
6. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydro pyrimidine dehyrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
7. Di Bartolomeo M, Bajetta E, Somma L, Carnaghi C, Bandieri E, Del Vecchio M, Gallo Stampino C, Buzzoni R: Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 1996;53:54-57.
8. Mackean M, et al: Phase 1 and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977-2985.
9. Nishi M, Omori Y, Miwa K (Japanese Research Society for Gastric Cancer): Japanese Classification of Gastric Carcinoma. IV. Response Assessment of Chemotherapy for Gastric Carcinoma. Tokyo, Kanehara, 1995, pp 89-104.
10. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-197.
11. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M Tegafur-0.4M Gimestat-1M Otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
12. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ota K, Yoshida M, Kimura T, Kurihara M, Taketa C, Taguchi T, Terazawa T, Tominaga T, Furue H, Wakui A, Ogawa N: Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer - Multi-institutional cooperative study. Jpn J Cancer Chemother 1985;12:2044-2051.
13. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Veweij J: Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. Br J Cancer 1994;70:380-383.
14. Koizumi W, Saigenji K, Nakamura N, Okayasu I, Kurihara M: Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 1999;56:215-222.
15. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S: Angiogenic factor. Nature 1992;356:668.
16. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, Akiyama S: Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endo-thelial cell growth factor/thymidine phosphorylase. Cancer Res 1995;55:1687-1690.
17. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL: The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996;73:275-280.
18. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T, Aikou T: Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 1996;87:288-295.
19. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32:333-338.
20. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.